Smith & Nephew Exogen 2000 Labeling For Non-Union Fracture Approved
This article was originally published in The Gray Sheet
Executive Summary
Smith & Nephew will employ its 300-person direct sales force to promote an expanded indication for the Exogen 2000 low-intensity pulsed ultrasound device for treatment of non-union bone fractures, a market valued at roughly $110 mil.